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A b s t r a c t  
Most of the drugs are not soluble in water and they create major problem during formulation they 
also show poor bioavailability. Reduction in particle size of such drugs enhances the dissolution rate 
and bioavailability. Nano suspension a promising delivery used to enhance the solubility of 
hydrophobic drugs. Media milling and high pressure homogenization technique are used 
commercially to produce nano suspensions. Recently emulsion and micro emulsion as templates are 
used to produce nano suspension. They are administered by Parenteral, per oral, ocular and 
pulmonary routes. Now their application also extended to site specific delivery. This review describes 
the methods of pharmaceutical nanosuspension production, formulations and pharmaceutical 
applications in drug delivery as well as the marketed products.   Nanosuspensions consist of the 
pure poorly water-soluble drug without any matrix material suspended in dispersion. 




The formulation of poorly water soluble drugs has always been a 
challenging problem faced by pharmaceutical scientists and it is 
expected to increase because approximately 40% or more of the 
new chemical entities being generated through drug discovery 
programmes are poorly water-soluble1. Obviously poorly water-
soluble drugs show many problems in formulating them in 
conventional dosage forms. One of the critical problems 
associated with poorly soluble drugs is too low bioavailability 
and/or erratic absorption2. The problem is even more intense for 
drugs such as itraconazole and carbamazepine (belonging to 
Biopharmaceutical Classification Scheme Class II (BCS CLASS 
II)) as classified by BCS System3,4 as they are poorly soluble in 
both aqueous and organic media, and for those drugs having a 
log P value of 2. The performance of these drugs is dissolution 
rate-limited (for Class II and III drugs) and is affected by the 
fed/fasted state of the patient. Dissolution rates of sparingly 
soluble drugs are related to the shape as well as the particle size. 
Therefore decrease in particle size results in an increase in 
dissolution rate5. There are number of formulation approaches 
that can be used to resolve the problems associated with the low 
solubility and low bioavailability of these class II drugs. Some of 
the approaches to increase solubility include micronization, 
solubilisation using co-solvents, use of permeation enhancers, oily 
solutions, surfactant dispersions6, salt formation7 and precipitation 
techniques8,9. Most of these techniques for solubility 
enhancement have advantages as well as some limitations and 
hence have limited utility in solubility enhancement. Other 
techniques used for solubility enhancement like microspheres, 
emulsions, microemulsions10, liposomes11, super critical 
processing, solid-dispersions12 and inclusion complexes using 
cyclodextrins13 show reasonable success but they lack in 
universal applicability to all drugs. These techniques are not 
applicable to the drugs, which are not soluble in both aqueous 
and organic media. However, there still remains an unmet need to 
equip the pharmaceutical industry with particle engineering 
technologies capable of formulating the poorly soluble drugs to 
improve their efficacy and to optimize therapy with respect to 
pharmacoeconomics. Nanosuspensions have revealed their 
potential to tackle the problems associated with the delivery of 
poorly water-soluble and poorly water-and lipid-soluble drugs, and 
are unique because of their simplicity and the advantages they 
confer over other strategies. This review focuses on the various 
aspects of nanosuspensions and their potentials as promising 
strategy in drug delivery. Nanotechnology is defined as the 
science and engineering carried out in the nanoscale that is 10-9 
meters14. Nanotechnology and nanoscience are widely seen as 
having a great potential to bring benefit to vast areas of research 
and applications. Nanodevices are somewhere 100 to 10000 
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biological molecules such as enzymes and receptors. This offers 
the unprecedented and paradigm changing oppurtunity to study 
and interact with normal as well as cancer cells at the molecular 
and cellular level scales and during the earliest stages of the 
cancer process. Nanoscale device can readily interact with 
biomolecules on both the surfaces of cells & inside of cells. 
Nanogen develops this technology. Nanogens technology utilizes 
the natural (+ve) or (-ve) charge of most biological molecules15. 
Nanoparticles 
Nanoparticles are solid polymeric, submicronic colloidal systems 
that range between 5-300nm consisting of macromolecular 
substances that vary in size 10nm to 100nm. The drug of interest 
is dissolved, entrapped adsorbed, attached or encapsulated into 
the nanoparticle matrix16. Depending upon the method of 
preparation, nanoparticles, nanospheres or nanocapsules can be 
obtained. Nanocapsules are systems in which the drug is confined 
to a cavity surrounded by a unique polymer membrane, while 
nanospheres are matrix systems in which the drug is physically 
and uniformly dispersed. In recent years, biodegradable polymeric 
nanoparticles, particularly those coated with hydrophilic polymer 
such as poly (ethylene glycol) (PEG) known as long-circulating 
particles, have been used as potential drug delivery devices 
because of their ability to circulate for a prolonged period time 
target a particular organ, as carriers of DNA in gene therapy, and 
their ability to deliver proteins, peptides and genes17,18. The 
advantages of using nanoparticles for nanoparticles loaded with 
drugs because of their small size can penetrate through small 
capillaries and are taken up by cells and allow the drug release at 
right rate and dose at specific sites in the body for a certain time 
to release the accurate delivery, which enhances the therapeutic 
effect and reduces the toxicity and side effects. The use of 
biodegradable materials for nanoparticles preparation allows 
sustained release within the target site over a period of days or 
even weeks. In spite of these advantages, nanoparticles do have 
limitations. For example, their small size and large surface area 
can lead to particle-particle aggregation, making physical handling 
of nanoparticles difficult in liquid and dry forms. In addition, small 
particles size and large surface area readily result in limited drug 
loading and burst release. These practical problems have to be 
overcome before nanoparticles can be used clinically or made 
commercially available. The cytotoxicity of polymers and the lack 
of a suitable large scale production are the drawbacks of 
polymeric nanoparticles. To overcome these drawbacks, solid 
lipid nanoparticles are preferred. 
Solid lipid nanoparticles  
Solid lipoid nanoparticles are one of the novel potential colloidal 
carriers19 in the range of 100-150nm as alternative materials to 
polymers which is identical to oil in water emulsion for parenteral 
nutrition, but the liquid lipid of the emulsion has been replaced by 
a solid lipid 20. They have many advantages such as good 
biocompatibility, low toxicity and lipophillic drugs are better 
delivered by solid lipid nanoparticles and the system is physically 
stable. Solid lipid nanoparticles may be a promising sustained 
release and drug targeting system for lipophilic CNS antitumor 
drugs16. 
Drug Nanocrystals 
Drug nanocrystals are pure solid drug particles with a mean 
diameter below 1000 nm. The term drug nanocrystals implies a 
crystalline state of the discrete particles, but depending on the 
production method they can also be partially or completely 
amorphous. Drug nanocrystals have to be distinguished from 
polymeric nanoparticles21, which consist of a polymeric matrix and 
an incorporated drug. Drug nanocrystals do not consist of any 
matrix material. 
Nanosuspensions 
Nanosuspensions are sub-micron colloidal dispersions of 
nanosized drug particles stabilized by surfactants22. 
Nanosuspensions consist of the poorly water-soluble drug without 
any matrix material suspended in dispersion23. These can be 
used to enhance the solubility of drugs that are poorly soluble in 
aqueous as well as lipid media. As a result of increased solubility, 
the rate of flooding of the active compound increases and the 
maximum plasma level is reached faster. Nanosuspensions can 
successfully formulate the brick dust molecules for improved 
dissolution and good absorption. Apart from this, 
nanosuspensions have some following advantages: Firstly, drugs 
no longer need to be in the soluble form. It is effective for those 
molecules insoluble in oils. Secondly, the high drug loading can 
be achieved as a drug exists in the form of pure solids, and can 
significantly reduce the administration volume of high dose. 
Thirdly, nanosuspensions can increase the physical and chemical 
stability of drugs as they are actually in the solid state. Finally, 
nanosuspensions can provide the passive targeting 24. 
Preparation Methods of Nanosuspensions 
Preparation of nanosuspensions are reported to be more cost 
effective and technically more simpler alternative than liposomes 
and other conventional colloidal drug carriers, particularly for 
poorly soluble drugs and yield a physically more stable product. 
The principle techniques used in recent years for preparing 
nanosuspensions can be classified into four basic methods: (a) 
Homogenization (b) Wet milling (c) Emulsification-solvent 
evaporation and (d) Precipitation or micro precipitation method. 
Nanosuspension engineeringprocesses currently used are 
preparation by precipitation, high pressure homogenization, 
emulsion and milling techniques25. For the nanosuspensions 
manufacture, there are two converse methods -‘bottom-up’ and 
the ‘topdown’ technologies26. The bottom-up technology is an 
assembling method from molecules to nanosized particles, 
including microprecipitation, microemulsion, melt emulsification 
method and so on. The top down technology is a disintegration 
approach from large particles, microparticles to nanoparticles, 
such as high-pressure homogenization and media milling method. 
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The ‘Top Down Technologies’ are the disintegration methods and 
are preferred over the precipitation methods. These include Media 
Milling (Nanocrystals), High Pressure Homogenization in water 
(Dissocubes), High Pressure Homogenization in nonaqueous 
media (Nanopure) and combination of Precipitation and High-
Pressure Homogenization (Nanoedege). Few other techniques 
used for preparing nanosuspensions are emulsion as templates 
and microemulsion as templates. 
Media milling 
Media milling is a further technique used to prepare 
nanosuspensions27,28. This patent-protected technology is 
acquired by Elan Drug Delivery29. In this technique, the 
nanosuspensions are produced using high-shear media mills or 
pearl mills. The media mill consists of a milling chamber, a milling 
shaft and a recirculation chamber. The drug nanoparticles are 
obtained by subjecting the drug to media milling. High energy and 
shear  forces generate as a result of impaction of the milling 
media with the drug provide the necessary energy input to 
disintegrate the microparticulate drug into nanosized particles. 
The milling medium is usually composed of glass, zirconium oxide 
or highly cross-linked polystyrene resin. In batch mode, the time 
required to obtain dispersions with unimodal distribution profiles 
and mean diameters <200nm is 30–60 min. In the media milling 
process, the milling chamber is charged with the milling media, 
water or suitable buffer, drug and stabilizer. Then milling media or 
pearls are rotated at a very high shear rate. Drugs like 
cilostazol30, danazol and naproxen.  In nanosuspensions, the 
particles are charged with polymeric media. The mill can be 
operated in a batch or recirculation mode. Slurry consisting of 
drug, water and stabilizer is fed into the milling chamber and 
processed into nanocrystalline dispersion. 
Principle 
The high energy and shear forces generate as a result of the 
impaction of the milling media with the drug provide the energy 
input to break the microparticulate drug into nano-sized particles. 
The milling medium is composed of glass, zirconium oxide or 
highly cross-linked 
polystyrene resin. The process can be performed in either batch 
or recirculation mode. In batch mode, the time required to obtain 
dispersions with unimodal distribution profiles and mean 
diameters<200nm is 30–60 min. The media milling process can 
successfully process micronized and non-micronized drug 
crystals. Once the formulation and the process are optimized, 
very little batch-to-batch variation is observed in the quality of the 
dispersion. 
Advantages 
 (1). Very dilute as well as highly concentrated nnanosuspensions         
can be prepared by handling  1 mg/ml to 400 mg/ml drug quantity. 
(2) Nanosized distribution of final nanosized product 
Disadvantages 
1. The media milling technique is time consuming. 
2. Some fractions of particles are in the micrometer range. 
3. Scale up is not easy due to mill size and weight. 
Dry Co-Grinding 
Recently, nanosuspensions are obtained by dry milling 
techniques. Successful work is reported in preparing stable 
nanosuspensions using dry-grinding of poorly soluble drugs with 
soluble polymers and copolymers after dispersing in a liquid 
media31. Itoh et al32 reported that the colloidal particles formation 
of many poorly water soluble drugs like griseofulvin, glibenclamide 
and nifedipine obtained by grinding with polyvinylpyrrolidone 
(PVP) and sodium dodecylsulfate (SDS). Many soluble polymers 
and co-polymers such as PVP, polyethylene glycol (PEG), 
hydroxypropyl methylcellulose (HPMC) and cyclodextrin 
derivatives are used33. Physicochemical properties and 
dissolution of poorly water soluble drugs are improved by co-
grinding because of an improvement in the surface polarity and 
transformation from a crystalline to an amorphous drug34. Dry co-
grinding can be carried out easily and economically and can be 
conducted without organic solvents. The co-grinding technique 
can reduce particles to the submicron level and a stable. 
Clarithromycin34 and Glibenclamide35 nanosuspensions are 
prepared by this method. 
Advantages 
(1)  Easy process and no organic solvent required.  
 (2)  Require short grinding time.  
Disadvantages 
Generation of residue of milling media.  
High pressure homogenization 
It is the most widely used method for the preparation of the 
nanosuspensions of many poorly water soluble drugs36,37. 
Different methods are developed based on this principle for 
preparation of nanosuspensions are Dissocubes, Nanopure, 
Nanoedge, Nanojet technology. In the high pressure 
homogenization method, the suspension of a drug and surfactant 
is forced under pressure through a nanosized aperture valve of a 
high pressure homogenizer.  
Principle 
During homogenization, the fraction of drug particles is brought 
about by cavitation, high-shear forces and the collision of the 
particles against each other. The drug suspension, contained in a 
cylinder of diameter about 3 mm, passes suddenly through a very 
narrow homogenization gap of 25µm, which leads to a high 
streaming velocity. In the homogenization gap, according to 
Bernoulli’s equation, the dynamic pressure of the fluid increases 
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with the simultaneous decrease in static pressure below the 
boiling point of water at room temperature. In consequence, water 
starts boiling at room temperature, leading to the formation of gas 
bubbles, which implode when the suspension leaves the gap 
(called cavitation) and normal air pressure is reached again. The 
implosion forces are sufficiently high to break down the drug 
microparticles into nanoparticles. Additionally, the collision of the 
particles at high speed helps to achieve the nano-sizing of the 
drug. To improve the efficiency of nano-sizing, the addition of 
viscosity enhancers is advantageous in certain cases as 
increasing the viscosity increases the powder density within the 
dispersion zone (homogenization gap). As the homogenizer can 
handle varying pressures, ranging from 100 to 1500 bars, the 
effect of the homogenization pressure on the particle size should 
be investigated in each case in order to optimize the process 
parameters. It is expected that the higher the homogenization 
pressure, the lower the particle size obtained. Drugs like 
Albendazole, Azithromycin, Fenofibrate nanosuspensions are 
prepared by this method, 
Advantages 
1. Drugs that are poorly soluble in both aqueous and 
organic media can be easily formulated into 
nanosuspensions. 
2. Ease of scale-up and little batch-to-batch variation38. 
3. Narrow size distribution of the nanoparticulate drug 
present in the final product39 
Disadvantages 
1. Prerequisite of suspension formation using high-speed 
mixers before subjecting it to homogenization. 
2. High number of homogenization cycles.  
3. Possible contamination could occur from metal ions 
coming off from the walls.  
Precipitation 
Precipitation has been applied for years to prepare submicron 
particles within the last decade 40,41, especially for the poorly 
soluble drugs. Typically, the drug is firstly dissolved in a solvent. 
Then this solution is mixed with a miscible antisolvent in the 
presence of surfactants. Rapid addition of a drug solution to the 
antisolvent (usually water) leads to sudden supersaturation of 
drug in the mixed solution and generation of ultrafine crystalline or 
amorphous drug solids. This process involves two phases: nuclei 
formation and crystal growth. When preparing a stable 
suspension with the minimum particle size, a high nucleation rate 
but low growth rate is necessary. Both rates are dependent on 
temperature: the optimum temperature for nucleation might lie 
below that for crystal growth, which permits temperature 
optimization42. Carbamazepine43, Cyclosporine44, Griseofulvin45 
nanosuspensions are prepared by this method. 
Advantages 
 Simple process, Ease of scale up and Economical production.  
Disadvantages 
 Growing of crystals needs to be limit by surfactant addition. Drug 
must be soluble at least in one solvent.  
Emulsions as templates 
Apart from the use of emulsions as a drug delivery vehicle, they 
can also be used as templates to produce nanosuspensions. The 
use of emulsions as templates is applicable for those drugs that 
are soluble in either volatile organic solvent or partially water-
miscible solvent. Such solvents can be used as the dispersed 
phase of the emulsion. There are two ways of fabricating drug 
nanosuspensions by the emulsification method. 
             In the first method, an organic solvent or mixture of 
solvents loaded with the drug is dispersed in the aqueous phase 
containing suitable surfactants to form an emulsion. The organic 
phase is then evaporated under reduced pressure so that the 
drug particles precipitate instantaneously to form a 
nanosuspension stabilized by surfactants. Since one particle is 
formed in each emulsion droplet, it is possible to control the 
particle size of the nanosuspension by controlling the size of the 
emulsion. Optimizing the surfactant composition increases the 
intake of organic phase and ultimately the drug loading in the 
emulsion. Originally, organic solvents such as methylene chloride 
and chloroform were used46. 
              Another method makes use of partially water-miscible 
solvents such as butyl lactate, benzyl alcohol and triacetin as the 
dispersed phase instead of hazardous solvents47. The emulsion is 
formed by the conventional method and the drug nanosuspension 
is obtained by just diluting the emulsion. Dilution of the emulsion 
with water causes complete diffusion of the internal phase into the 
external phase, leading to instantaneous formation of a 
nanosuspension. The nanosuspension thus formed has to be 
made free of the internal phase and surfactants by means of 
diultrafiltration in order to make it suitable for administration. 
However, if all the ingredients that are used for the production of 
the nanosuspension are present in a concentration acceptable for 
the desired route of administration, then simple centrifugation or 
ultracentrifugation is sufficient to separate the nanosuspension. 
Advantages 
1. Use of specialized equipment is not necessary. 
2. Particle size can easily be controlled by controlling the 
size of the emulsion droplet. 
3. Ease of scale-up if formulation is optimized properly. 
Disadvantages 
1. Drugs that are poorly soluble in both aqueous and 
organic media cannot be formulated by this technique. 
2. Safety concerns because of the use of hazardous 
solvents in the process. 
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3. Need for diultrafiltration for purification of the drug 
nanosuspension, which may render the process costly. 
Microemulsions as templates 
Microemulsions are thermodynamically stable and 
isotropically,clear dispersions of two immiscible liquids, such as oil 
and water, stabilized by an interfacial film of surfactant and co-
surfactant 48. Their advantages, such as high drug solubilization, 
long shelf-life and ease 
of manufacture, make them an ideal drug delivery vehicle. There 
are several research papers available that describe the use of 
microemulsions as drug delivery vehicles40-52. 
Recently, the use of microemulsions as templates for the 
production of solid lipid nanoparticles53 and polymeric 
nanoparticles54 is described. Breviscapine55  nanosuspensions 
are prepared by this method. The drug can be either loaded in the 
internal phase or pre-formed microemulsions can be saturated 
with the drug by intimate mixing. The suitable dilution of the 
microemulsion yields the drug nanosuspension by the mechanism 
described earlier. The influence of the amount and ratio of 
surfactant to co-surfactant on the uptake of internal phase and on 
the globule size of the microemulsion should be investigated and 
optimized in order to achieve the desired drug loading. The 
nanosuspension thus formed has to be made free of the internal 
phase and surfactants by means of diultrafiltration in order to 
make it suitable for administration. However, if all the ingredients 
that are used for the production of the nanosuspension are 
present in a concentration acceptable for the desired route of 
administration, then simple centrifugation or ultracentrifugation is 
sufficient to separate the nanosuspension. 
Advantages 
High drug solubilisation,  Long shelf life and Ease of manufacture.  
Disadvantages 
Use of high amount of surfactant and stabilizers and Use of 
hazardous solvent in production.  
Formulation considerations 
Stabilizer 
Stabilizer plays an important role in the formulation of 
nanosuspensions. In the absence of an appropriate stabilizer, the 
high surface energy of nano-sized particles can induce 
agglomeration or aggregation of the drug crystals. The main 
functions of a stabilizer are to wet the drug particles thoroughly, 
and to prevent Ostwald’s ripening56 and agglomeration of 
nanosuspensions in order to yield a physically stable formulation 
by providing steric or ionic barriers. The type and amount of 
stabilizer has a pronounced effect on the physical stability and in-
vivo behaviour of nanosuspensions. In some cases, a mixture of 
stabilizers is required to obtain a stable nanosuspension. The 
drug-to-stabilizer ratio in the formulation may vary from 1:20 to 
20:1 and should be investigated for a specific case. Lecithin is the 
stabilizer of choice if one intends to develop a parenterally 
acceptable and autoclavable nanosuspension. 
Organic solvents 
Organic solvents may be required in the formulation of 
nanosuspensions if they are to be prepared using an emulsion or 
microemulsion as a template. As these techniques are still in their 
infancy, elaborate information on formulation considerations is not 
available. The acceptability of the organic solvents in the 
pharmaceutical arena, their toxicity potential and the ease of their 
removal from the formulation need to be considered when 
formulating nanosuspensions using emulsions or microemulsions 
as templates. The pharmaceutically acceptable and less 
hazardous water-miscible solvents, such as ethanol and 
isopropanol, and partially water-miscible solvents, such as ethyl 
acetate, ethyl formate, butyl lactate, triacetin, 
propylene carbonate and benzyl alcohol, are preferred in the 
formulation over the conventional hazardous solvents, such as 
dichloromethane. Additionally, partially water miscible organic 
solvents can be used as the internal phase of the microemulsion 
when the nanosuspensions are to be produced using a 
microemulsion as a template. 
Co-surfactants 
The choice of co-surfactant is critical when using microemulsions 
to formulate nanosuspensions. Since co-surfactants can greatly 
influence phase behaviour, the effect of 
co-surfactant on uptake of the internal phase for selected 
microemulsion composition and on drug loading should be 
investigated. Although the literature describes the use of bile salts 
and dipotassium glycerrhizinate as co-surfactants, various 
solubilizers, such as Transcutol, glycofurol, ethanol and 
isopropanol, can be safely used as co-surfactants in the 
formulation of microemulsions. 
Other additives 
Nanosuspensions may contain additives such as buffers, salts, 
polyols, osmogent and cryoprotectant, depending on either the 
route of administration or the properties of the drug moiety. 
Post-production processing 
Post-production processing of nanosuspensions becomes 
essential when the drug candidate is highly susceptible to 
hydrolytic cleavage or chemical degradation. Processing may also 
be required when the best possible stabilizer is not able to 
stabilize the nanosuspension for a longer period of time or there 
are acceptability restrictions with respect to the desired route. 
Considering these aspects, techniques such as lyophillization or 
spray drying may be employed to produce a dry powder of nano-
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sized drug particles. Rational selection has to be made in these 
unit operations considering the drug properties and economic 
aspects. Generally, spray drying is more economical and 
convenient than lyophillization. The effect of post-production 
processing on the particle size of the nanosuspension and 
moisture content of dried nanosized drug should be given due 
consideration. 
Advantages of nanosuspensions 
Increase in the dissolution velocity and 
saturation solubility of the drug 
The reason of nanosuspensions being a promising drug delivery 
strategy  behind the increase in the dissolution velocity and 
saturation solubility of the nanosuspensions can be given as 
follows. According to the Nernst–Brunner and Levich modification 
of the Noyes Whitney dissolution model equation57, the 
dissolution velocity of the nanosuspension increases due to a 
dramatic increase in the surface area of the drug particles from 
microns to particles of nanometer size: 
 
                       dX/dt¼((DxA)/h) (CsxX/V) 
 
dX/dt - dissolution velocity, D - diffusion coefficient, A - surface 
area of the particle, h - diffusional distance, Cs - saturation 
solubility of the drug, X - concentration in the surrounding liquid 
and V - volume of the dissolution medium. 
Improved biological performance 
An increase in the dissolution velocity and saturation solubility of a 
drug leads to an improvement in the invivo performance of the 
drug irrespective of the route used. The advantages related to 
various routes are discussed later in detail. 
Ease of manufacture and scale-up 
Unlike nanoparticulate carriers such as polymeric nanoparticles, 
which were investigated earlier, nanosuspensions are easy to 
manufacture. The production processes described earlier are 
easily scaled up for commercial production. The introduction of 
nanosuspension products such as Rapamune and the 
NanoCrystal colloidal ketoprofen is sufficient to substantiate this 
Long-term physical stability 
Another special feature of nanosuspensions is the absence of 
Ostwald ripening, which is suggestive of their long-term physical 
stability58. Ostwald ripening is described for ultrafine dispersed 
systems and is responsible for crystal growth and subsequently 
formation of microparticles. Ostwald ripening is caused by the 
differences in dissolution pressure/saturation solubility between 
small and large particles. It is in practice an effect based on the 
higher saturation solubility of very small particles as compared to 
larger ones. Molecules diffuse from the higher concentrated area 
around small particles (higher saturation solubility) to areas 
around larger particles possessing a lower drug concentration. 
This leads to the formation of a supersaturated solution around 
the large particles and consequently to drug crystallization and 
growth of the large particles. The diffusion process of the drug 
from the small particles to the large particles leaves an area 
around the small particles that is not saturated any more, 
consequently leading to dissolution of the drug from the small 
particles. Finally there is complete disappearance of the small 
particles. The lack of Ostwald ripening in nanosuspensions is 
attributed to their uniform particle size, which is created by various 
manufacturing processes. The absence of particles with large 
differences in their size in nanosuspensions prevents the 
existence of the different saturation solubilities and concentration 
gradients in the vicinity of differently sized particles, which in turn 
prevents the Ostwald ripening effect. 
Versatility 
The flexibility offered in the modification of surface properties and 
particle size, and ease of post-production processing of 
nanosuspensions enables them to be incorporated in various 
dosage forms, such as tablets, pellets, suppositories and 
hydrogels, for various routes of administration, thus proving their 
versatility. 
Characterization of nanosuspensions 
Mean particle size and particle size 
distribution 
The mean particle size and the span of particle size distribution 
(polydispersity index, PI) are two important characteristic 
parameters because they affect the saturation solubility, 
dissolution rate, physical stability, even in-vivo behavior of 
nanosuspensions. It is indicated by Muller & Peters (1998) that 
saturation solubility and dissolution velocity show considerable 
variation with the changing, particle size of the drug59. Particle 
size distribution determines the physiochemical behavior of the 
formulation, such as saturation solubility, dissolution velocity and 
physical stability. The particle size distribution can be determined 
by photon correlation spectroscopy (PCS), laser diffraction (LD) 
and coulter counter multisizer. PCS can even be used for 
determining the width of the particle size distribution 
(polydispersity index, PI). The PI is an important parameter that 
governs the physical stability of nanosuspensions and should be 
as low as possible for the long-term stability of nanosuspensions. 
A PI value of 0.1– 0.25 indicates a fairly narrow size distribution 
whereas a PI value greater than 0.5 indicates a very broad 
distribution. The coulter-counter gives the absolute number of 
particles per volume unit for the different size classes, and it is a 
more efficient and appropriate technique than LD for quantifying 
the contamination of nanosuspensions by microparticulate drugs. 
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Surface charge (zeta potential) 
Zeta potential gives certain information about the surface charge 
properties and further the long-term physical stability of the 
nanosuspensions.The zeta potential of a nanosuspension is 
governed by both the stabilizer and the drug itself . For a stable 
suspension stabilized only by electrostatic repulsion, a minimum 
zeta potential of  ±30 mV is required whereas in case of a 
combined electrostatic and steric stabilizer, a zeta potential of  
±20 mV would be sufficient. 
Crystalline state and particle morphology 
The assessment of the crystalline state and particle morphology 
together helps in understanding the polymorphic or morphological 
changes that a drug might undergo when subjected to nanosizing. 
Nanosuspensions can undergo a change in the crystalline 
structure, which may be to an amorphous form or to other 
polymorphic forms because of high-pressure homogenization The 
changes in the solid state of the drug particles as well as the 
extent of the amorphous fraction can be determined by X-ray 
diffraction analysis60,61 and supplemented by differential scanning 
calorimetry62. In order to get an actual idea of particle 
morphology, scanning electron microscopy is preferred. 
Saturation solubility and dissolution velocity 
Nanosuspensions have an important advantage over other 
techniques, that it can increase the dissolution velocity as well as 
the saturation solubility. The saturation solubility of the drug in 
different physiological buffers as well as at different temperatures 
should be assessed using methods described in the literature. 
The investigation of the dissolution velocity of nanosuspensions 
reflects the advantages that can be achieved over conventional 
formulations, especially when designing the sustained-release 
dosage forms based on nanoparticulate drugs. The assessment 
of saturation solubility and dissolution velocity helps in 
determining the in vitro behavior of the formulation 
In vivo evaluation 
The in vivo evaluation of the nanosuspensions is specific to drug 
and route of administration. The parameters which are generally 
evaluated in vivo are 
1. Surface hydrophilicity/hydrophobicity (determines 
interaction with cells prior to phagocytosis)  
2. Adhesion properties  
Applications of nanosuspensions in drug 
delivery 
Oral drug delivery 
The oral route is the preferred route for drug delivery because of 
its numerous well-known advantages. The efficacy or 
performance of the orally administered drug generally depends on 
its solubility and absorption through the gastrointestinal tract. 
Hence, a drug candidate that exhibits poor aqueous solubility 
and/or dissolution-rate limited absorption is believed to possess 
low and/or highly variable oral bioavailability. Owing to low oral 
bioavailability, such a drug candidate would have to be 
administered in a larger excess than actually required if it were 
completely bioavailable in order to achieve a therapeutically active 
concentration, thus making the therapy costly. Orally administered 
antibiotics such as atovaquone and bupravaquone reflect this 
problemvery well. Nanosizing of such drugs can lead to a 
dramatic increase in their oral absorption and subsequently 
bioavailability. The amelioration in oral bioavailability can be 
attributed to the adhesiveness of the drug nanosuspension, 
increased surface area (due to reduction in particle size by 10–50-
fold), increased saturation solubility, leading to an increased 
concentration gradient between the gastrointestinal tract lumen 
and blood, and increased dissolution velocity. This enhancement 
in bioavailability will lead to a subsequent reduction in drug dose, 
rendering the therapy cost-effective and obliterating any undue 
drug dumping in the body. Amphotericin B, a highly effective 
polyene antibiotic used for systemic mycoses and leishmaniasis 
lacks oral bioavailability. However, oral administration of 
amphotericin B as a nanosuspension produced a substantial 
improvement in its oral absorption in comparison to orally 
administered conventional commercial formulations such as 
Fungizone, AmBisome and micronized amphotericin B62. 
Nanosuspensions are also advantageous in achieving quick onset 
of action for drugs that are completely but slowly absorbed, i.e. 
those having high tmax values. This is illustrated by the study 
carried out for naproxen, a nonsteroidal anti-inflammatory drug. A 
dosage form with fast onset of action would be highly desirable for 
naproxen63. 
Ophthalmic drug delivery 
Nanosuspensions could prove to be vital for drugs that exhibit 
poor solubility in lachrymal fluids. Suspensions offer advantages 
such as prolonged residence time in a cul-de-sac, which is 
desirable for most ocular diseases for effective treatment and 
avoidance of high tonicity created by water soluble drugs. Their 
actual performance depends on the intrinsic solubility of the drug 
in lachrymal fluids. Thus the intrinsic dissolution rate of the drug in 
lachrymal fluids governs its release and ocular bioavailability. 
However, the intrinsic dissolution rate of the drug will vary 
because of the constant inflow and outflow of lachrymal fluids. 
One example of a nanosuspension intended for ophathamic 
controlled delivery was developed as a polymeric nanosuspension 
of ibuprofen64. This nanosuspension is successfully prepared 
using Eudragit RS100 by a quasi-emulsion and solvent diffusion 
method. Nanosuspensions of glucocorticoid drugs; 
hydrocortisone, prednisolone and dexamethasone enhance rate, 
drug absorption and increase the duration of drug action65. 
Pulmonary drug delivery 
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Aqueous nanosuspensions can be nebulized using mechanical or 
ultrasonic nebulizers for lung delivery. Basically the 
nanosuspensions can be used in all nebulizers. The dispersions 
can be relatively high concentrated. Due to the presence of many 
small particles instead of a few large microparticles, all aerosol 
droplets are likely to contain drug nanoparticles. Budesonide, a 
poorly water-soluble corticosteroid, has been successfully 
prepared as a nanosuspension for pulmonary delivery66. A good 
relationship was obtained between increasing the drug 
concentration in the formulation and the number of micrograms of 
drug delivered per actuation. In addition, bupravaquone 
nanosuspensions were formulated for treatment of lung infections 
by using nebulisation67. 
Parenteral administration 
Nanosuspensions can be administered via different parenteral 
administration routes ranging from intra-articular via intraperitonal 
to intravenous injection. For administration by the parenteral 
route, the drug either has to be solubilized or has particle/globule 
size below 5 μm to avoid capillary blockage. The current 
approaches for parenteral delivery include salt formation, 
solubilization using co-solvents, micellar solutions, complexation 
with cyclodextrin and recently liposomes. However, there are 
limitations on the use of these approaches because of the 
limitations on their solubilization capacity and parenteral 
acceptability. In this regard, liposomes are much more tolerable 
and versatile in terms of parenteral delivery. However, they often 
suffer from problems such as physical instability, high 
manufacturing cost and difficulties in scale-up. Nanosuspensions 
would be able to solve the problems mentioned above. In 
addition, nanosuspensions have been found to increase the 
efficacy of parenterally administered drugs. Paclitaxel 
nanosuspensions revealed their superiority over taxol in reducing 
the median tumour burden68. Similarly, aphidicolin, a poorly water 
soluble new anti-parasitic lead molecule, when administered as a 
nanosuspension resulted in an improvement in EC50 in 
comparison to DMSO-dissolved drug69. Rainbow and co-workers 
reported an intravenous itraconazole nanosuspension enhanced 





Target drug delivery 
Nanosuspensions can also be used for targeted delivery as their 
surface properties and in vivo behavior can easily be altered by 
changing either the stabilizer or the milieu. Their versatility, ease 
of scale up and commercial product enable the development of 
commercial viable nanosuspensions for targeted delivery. The 
engineering of stealth nanosuspensions by using various surface 
coatings for active or passive targeting of the desired site is the 
future of targeted drug delivery systems. Targeting of 
Cryptosporidium parvum, the organism responsible for 
cryptosporidiosis, was achieved by using surface modified 
mucoadhesive nanosuspensions of bupravaquone71. 
Topical formulations 
Drug nanoparticles can be incorporated into creams and water-
free ointments. The nanocrystalline form leads to an increased 
saturation solubility of the drug in the topical dosage form, thus 
enhancing the diffusion of the drug into the skin72,73. 
Conclusion 
The dissolution problems of poorly water soluble drugs have been 
largely solved to improve drug absorption and bioavailability. 
Nanosuspension formulations are promising candidates for 
enhancing the solubility of poorly water soluble drugs. 
Nanosuspension technology can be combined with traditional 
dosage forms: tablets, capsules, pellets, and can be used for 
parenteral products. To take advantage of nanosuspension drug 
delivery, simple formation technologies and variety applications, 
nanosuspensions will continue to be of interest as oral 
formulations and non-oral administration develop in the future. 
Production techniques such as media milling and high-pressure 
homogenization have been successfully employed for large-scale 
production of nanosuspensions. The advances in production 
methodologies using emulsions or microemulsions as templates 
have provided still simpler approaches for production but with 
limitations. Further investigation in this regard is still essential. 
Attractive features, such as increased dissolution velocity, 
increased saturation solubility, improved bioadhesivity, versatility 
in surface modification and ease of post-production processing, 
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Figure 1: Schematic cartoon of the high-pressure homogenization process 
 
 
Table:1.0 Current marketed pharmaceutical products utilizing nanocrystalline formation. 
 
Product                                                compound name                    company name 
 
RAPAMUNE®                                       Sirolimus                             Wyeth 
EMEND®                                               Aprepitant                           Merck 
TriCor®                                                   Fenofibrate                         Abbott 
MEGACE® ES                                       Megestrol acetate                 PAR pharmaceutical 




Table: 2.0 Potential benefits of nanosuspension technology 
 
Route of administration                                 Potential benfits 
 
                                                                          Rapid dissolution and high  
Oral                                                                                     bioavailability 
Intravenous (I.V)                                                                Tissue targeting 
                                                                                            Rapid dissolution 
                                                                                            Longer duration of retention in                    
 systemic circulation 
Occular                                                                               High bioavailability 
                                                                                            Lesser irritation 
Subcutaneous/intramuscular                                              High bioavailability 
                                                             Rapid onset of action 
